Overview

The Long COVID Treatment Trial

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
Phase:
PHASE2
Details
Lead Sponsor:
Scripps Translational Science Institute
Collaborator:
Schmidt Initiative for Long COVID
Treatments:
Tirzepatide